NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/02/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization392.59 mln
Float123 mln
Earnings Date08/05/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
8.50
Transformational upside
Relative Strength
87
/ 100
Strongly outperforming
Debt / Equity
0.05
Debt-free
ROE
-42.80
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Compass Therapeutics is a Boston-based clinical-stage company focused on developing antibody-based treatments for cancer. Its lead drug candidate, tovecimig, works by blocking two proteins that tumors rely on to build their blood supply, potentially cutting off the resources cancer cells need to grow and spread. The company is also advancing several other experimental treatments designed to help the immune system recognize and attack cancer more effectively. Founded in 2014, Compass Therapeutics is working to build a broad portfolio of therapies that address some of the most challenging aspects of treating cancer.
